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Abstract: Haemophilia replacement factors, both plasma-
derived and recombinant, are in relatively short supply and are
high-cost products. This has stymied the study and develop-
ment of alternative methods of administration of haemophilia
therapy even in the most economically advanced countries,
owing to the large amounts of material needed because
bioabsorption and bioavailability of haemophilic factors can be
less than 10% when using non-intravenous routes of delivery.
There is therefore a need to increase access to therapy world-
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wide by decreasing the cost and increasing the abundance so
that therapy can be achieved through simplified, alternative
delivery methods. Transgenic livestock have been used to pro-
duce haemophilic factors in milk. Only the pig mammary gland
has been shown to carry out the post-translational processing
necessary to enable both the biological activity and long circu-
lation half-life needed for therapeutic glycoproteins. Further-
more, the large amounts of recombinant protein that can be
produced from pig milk make feasible the use of alternative
delivery methods such as oral, intratracheal, subcutaneous,
and intramuscular administration.
Keywords: factor IX, haemophilia, transgenic animal
Introduction
The haemophilias are congenital disorders characterized by
frequent bleeding episodes, especially into the joints and
muscles, that cause severe arthritis and crippling. Untreated
severe haemophilia patients rarely survive past adolescence.
The most common haemophilias are caused by congenital de-
ficiency in the clotting proteins factor (F) VIII (haemophilia A) or
FIX (haemophilia B), which occur in about 1 : 5,000 and 1 :
23,000 male children, respectively. These patients are currently
treated with replacement therapy using intravenous admini-
stration of purified FVIII or FIX produced by purification from
donor plasma or in cell-culture bioreactors. According to a
1995 audit in the state of California, the average healthcare
cost for haemophilia patients receiving what is now considered
suboptimal care was US$ 140,000 per patient per year of life
[1], of which the overwhelming majority represents the direct
cost of the clotting factor concentrate. Replacement of clotting
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factor after a haemorrhage is recognized as a suboptimal
treatment, as some damage still ensues. Optimal therapy con-
sists of regular replacement of the clotting factor to prevent
bleeding episodes. Some of the most urgent problems that
complicate the clinical situation include:
1. optimal care of patients in the developed countries is
not possible because of the high cost and insufficient
supply of clotting factors for replacement therapy;
2. there is currently no access to clotting factors for re-
placement therapy for 80% of the world's haemophili-
acs;
3. clotting factor shortages occur and are exacerbated by
raw material shortages (i.e. plasma) and production-
plant shutdowns;
4. there is a lack of affordable and adequate amounts of
clotting factors for alternative routes of administration,
such as oral dosage, which would circumvent the com-
plications and difficulties of intravenous therapy.
The high cost of purified haemophilic factor proteins se-
verely limits treatment in the most developed countries to
therapy needed when bleeding occurs (episodic treatment) [2],
and regrettably, little to no treatment for 80% of the world's
haemophilia A and B patients, who live in developing countries
[3]. Episodic therapy, compared with preventative or prophy-
lactic therapy, is suboptimal for severe haemophilia, but still
requires on average at least 50,000 international units (IU) of
FIX or more per patient per year [4] at an average wholesale
price of US$ 1.18 per IU [5]. The limited supply of donor
plasma, the low productivity of cell culture bioreactors, and
high development costs of about US$ 800,000,000 for a new
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therapeutic product [6] contribute to the high cost of haemo-
philic factor proteins. As a result, the limited supply of either
plasma or recombinant factors precludes the broad use of pro-
phylactic therapy, which is now regarded as the most effective
treatment to reduce the number of bleeding episodes and
prevent joint damage [7,8].
This paper discusses innovative bioengineering efforts that
would provide effective and affordable supplies of replacement
clotting factors and thus make possible methods of admini-
stration other than intravenous injection to treat haemophilia.
FIX is used as a detailed example, but it is recognized that
current research into production and alternative methods of
delivery for FVIII closely parallel that of FIX.
Molecular difficulties and ramifications in the
production of haemophilic factors
Several fundamental biochemical constraints are encountered
in the production of recombinant human FIX that make it a
scarce protein therapeutic. These constraints lie not only in the
relationship between the complexity of FIX function and its
structure, but also in the limited productivity that is inherent to
animal cells cultured on a large scale. The biological activity of
FIX requires a complex molecular structure that contains post-
translational modifications. Figure 1 shows the salient mo-
lecular features of FIX. FIX is a member of the vitamin K-de-
pendent family of proteins distinguished by the post-transla-
tional I-carboxylation of glutamate (Glu) to I-carboxygluta-
mate (Gla). This post-translational modification requires vita-
min K as a cofactor and the FIX propeptide as the binding site
for the carboxylase enzyme complex [9]. After the N-terminal
glutamates are I-carboxylated, the propeptide is removed.
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Fig. 1. FIX amino acid sequence, indicating the propeptide
(Thr-18–Arg1), post-translational modifications in the ‘Gla
domain’ (Tyr1–Glu40), and the activation peptide (Ala146–
Arg180).
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Both of these molecular processing steps are required for
biological activity. In terms of a therapeutic product
specification, FIX products must have at least 6 I-carboxyglu-
tamates per molecule to be functional [10]. The complexity of
these post-translational modifications necessitates production
of biologically active FIX in mammalian cells. However, very few
mammalian cells are capable of making these post-transla-
tional modifications at rates sufficient for commercial-scale
production.
Because of the rate limitations in post-translational modi-
fication, animal cells will produce a mixture of FIX molecules.
Purification processing is then used to enrich the FIX mixture
with species having the most desirable therapeutic properties.
BeneFix® manufacture provides a good illustration. BeneFix® is
the only recombinant human FIX product approved by the
United States Food and Drug Administration (USFDA), and it is
produced in Chinese hamster ovary cells. The source material
collected from genetically engineered cell culture is widely di-
verse in the extent and variety of post-translational modifica-
tion of the FIX molecules; nevertheless, subsequent purification
processes yield a highly efficacious and safe therapeutic. The
problem of having a mixture of biologically active and inactive
FIX populations was solved by designing a purification process
consisting of four chromatographic steps designed to purify
and select for I-carboxylated recombinant FIX [11]. Briefly,
highly purified BeneFix® contains a mixture of subpopulations
with 10, 11 and 12 I-carboxyglutamates [12]. This is consis-
tent with the reported limitations in the ability of Chinese
hamster ovary cells to completely I-carboxylate FIX [10]. An-
other salient feature of BeneFix® is that, unlike plasma-derived
FIX products, it contains essentially no phosphorylation at
Ser158, and only 15% sulphation of Tyr155 [12]. Pharmacoki-
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netic studies in humans indicate that this lack of phosphoryla-
tion and sulphation may lead to a modestly lower initial recov-
ery of activity in plasma after intravenous infusion for Bene-
Fix®, compared with plasma-derived FIX [13].
Other post-translational modifications made to FIX include
N-hydroxylation of Asp63, two N-linked glycosylation sites at
Asn157 and Asn167 within the activation peptide, and four O-
linked glycosylation sites at Ser53, Ser61, Thr159, and Thr169
(Fig. 1). The specific contributions of these post-translational
modifications to FIX biological activity have not yet been de-
termined. However, the presence of terminal sialic acid moie-
ties on N-linked oligosaccharides has been shown to signifi-
cantly improve the circulation half-life of therapeutic proteins
[14]. Plasma-derived FIX has complex N-linked oligosaccha-
rides that are tri- and tetra-antennary and terminated with
sialic acid (N-acetylneuraminic acid) [15]. N-linked oligosac-
charides of BeneFix® are similar to plasma-derived FIX [12].
The production of FVIII by genetically engineered animal
cells is even more highly constrained by molecular complexity
than is FIX [16]. For example, FVIII is limited in its rate of se-
cretion, which is related to its post-translational structure.
Post-translational structures arising from proteolytic process-
ing, sulphation, and glycosylation each contribute to FVIII bio-
logical function. Some of these rate limitations can be amelio-
rated by molecular engineering of the primary structure of the
FVIII molecule while still maintaining or even improving the
function and stability [17]. However, even with these improve-
ments, the rate of synthesis and secretion of FVIII by any ani-
mal cell is arguably one of the most difficult tasks that has
been encountered in recombinant protein expression. Thus,
other improvements in production technology must be made to
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make FVIII abundant and less costly, such as increasing the
concentration of cells in the bioreactor.
Large-scale production characteristics of haemo-
philic factors made using plasma, cell culture or
transgenic mammary tissue
The primary cause of the current scarcity of haemophilic fac-
tors is that only low concentrations of FVIII and FIX occur in
human plasma, and only limited concentrations can be pro-
duced in the bioreactor culture of genetically engineered ani-
mal cells. FVIII is found in plasma at about 0.2 Og mL-1 and FIX
at only 5 Og mL-1. The exact concentrations of FVIII made in
animal cell bioreactors at production scale are not published by
manufacturers, but are likely to be much less than 10 Og mL-1
accumulated after about every 24–48 h of production phase.
FIX is also likely to be produced at similarly low concentrations
by large-scale bioreactors. The low concentration of recom-
binant haemophilic factor protein made by current animal-cell
culture technology is due to two process limitations: a low
concentration of cells of about 5 × 106 cells mL-1 of reactor
volume and low production of protein made by each animal
cell. While on a per cell basis, recombinant protein production
has been increased by genetic engineering of both the protein
and the cell itself, very little progress has been made in raising
the concentration of cells that can be cultured at manufactur-
ing scale.
The resultant low concentration of these haemophilic fac-
tors in the bioreactor dictates that downstream processing
must both concentrate and purify the final product at very high
cost [18]. Typically, the overall production costs will be on the
order of about US$ 10,000 or more per gram of recombinant
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protein. For FVIII and FIX, this translates to a direct manufac-
turing cost on order of US$ 0.10 per unit. More importantly,
the exceedingly large production volumes needed to satisfy
clinical demands require very costly investments in manufac-
turing facilities. Specifically, a large portion of the cost is as-
sociated with both establishing and maintaining the validated
status of large-scale processes needed to consistently produce
material that will meet federal regulatory requirements [6,19].
The limitations in current manufacturing capacity have a seri-
ous impact on haemophilia therapy. For example, even though
about 90% of patients in the USA receive recombinant FIX
therapy, only 13% of the children with haemophilia B in the USA
receive prophylaxis [20].
The projected process volumes needed to satisfy the esti-
mated clinical demand for prophylactic intravenous therapy for
FIX in the USA translate to large capital investment costs in new
manufacturing facilities [19]. Figure 2 compares the estimated
amounts of FIX source materials needed to meet the demand
for prophylactic intravenous therapy for the estimated 3,000
patients at a level of 200,000 IU patient-1 year-1. To satisfy this
demand using plasma-derived FIX would require processing
over 1 million litres of plasma per year. A comparable amount
of recombinant FIX produced using industry-standard cell-
culture bioreactors would require 600,000 L of supernatant per
year and greater than US$ 50,000,000 capital investment. In
contrast to both plasma and animal cell culture, only 60 ge-
netically engineered pigs that produce FIX in their milk would
be needed to supply prophylactic intravenous treatment to the
3,000 patients in the USA.
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Fig. 2. Volumes of source materials for FIX required to meet the
needs for prophylactic therapy of all haemophilia B patients in
the USA (3,000 patients @200,000 IU per patient per year). The
amount of FIX in each source is – plasma (1 IU mL-1); CHO cell
bioreactor (2 IU mL-1) and transgenic pig milk (100 IU mL-1,
Lindsay et al. 2004). A 50% purification yield for each source is
assumed. The milk of 60 pigs (12,000 L year-1) could supply
the entire amount of FIX needed for prophylaxis in the USA.
Transgenic animal production of haemophilic factors
The milk of transgenic livestock can be a prodigious and expe-
dient source of complex therapeutic proteins such as recombi-
nant haemophilic factors relative to cell culture bioreactors
[21]. When considered as potential bioreactors, mammary tis-
sues can produce high concentrations of secreted proteins,
owing to the high cell density of the gland, with about 109 cells
mL-1 of tissue. This cell density is 2–3 orders of magnitude
greater than that possible in mammalian cell-culture produc-
tion technology used to make complex recombinant therapeu-
tic proteins. The result is remarkable protein production rates
of about 1–15 g L-1 h-1 in milk. The specific choice of making
haemophilic factors in the pig rather than other livestock is
based in part upon the combination of high volume of milk
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that can be harvested per day (1–3 L) and the quality of post-
translational processing of complex proteins by pig mammary
cells relative to other animal cells. A transgenic pig typically
yields about 0.4–1.25 L per milking. Pigs can be milked up to
five times per day over two 50-day lactations per year, and so
the total milk yield from the average sow is 100–300 L year-1
[21]. Even more important than the consideration of milk vol-
ume, however, is the fact that the mammary epithelial cells of
the pig are unique among livestock in making the complex
post-translational modifications needed for FIX [22] and FVIII
[23] biological activity. From a broad biochemical and physio-
logical perspective, the pig is more closely related to humans
than the ruminants, which include the cow, sheep, and goat. As
an example of the differences between ruminant and pig bio-
chemistry, recombinant FIX production in sheep was unsuc-
cessful, with only low levels of biologically active FIX being
produced: less than 0.5 ng of biologically active FIX could be
recovered from each millilitre of milk [24]. The sheep was even
less productive than donor plasma at 0.0001 U mL-1 of milk. In
contrast, recombinant human FIX has been produced at levels
up to 100 U mL-1 of milk in transgenic pigs [22], and proper
proteolytic cleavage of recombinant FVIII to a mature two-chain
form has been demonstrated in the milk [23]. With respect to
N-linked glycans that are needed for long circulation half-life
in therapeutic proteins [14], endogenous porcine milk glyco-
proteins such as lactoferrin contain complex glycans termi-
nated with N-acetylneuraminic acid (sialic acid) [25]. In con-
trast, ruminant lactoferrins contain undesirable high-mannose
glycans [25], and recombinant antithrombin III produced in
transgenic goats also contained high-mannose glycans [26].
Thus, ruminants are probably unable to make a recombinant
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FIX or FVIII with the glycosylation needed for a long circulation
half-life.
The safety requirements for USFDA approval of a
transgenic animal supply of recombinant haemo-
philic factors
The regulatory concerns for production of haemophilic factors
derived from transgenic animals have been largely delineated.
In recognition of the feasibility of this production method, the
USFDA has issued a document, Points to Consider in the
Manufacture and Testing of Therapeutic Products for Human
Use Derived from Transgenic Animals. Importantly, pioneering
work on the safety and efficacy of recombinant antithrombin III
produced in the milk of transgenic animals has been demon-
strated in clinical trials by Genzyme Transgenics Corporation
[27]. To reduce risks of disease transmission, multiple barriers
(chromatography, solvent/detergent treatment, and nanofiltra-
tion) can be placed in the purification process to provide logs
of pathogen removal and/or inactivation of common classes of
lipid-enveloped and non-lipid-enveloped viruses. Maintenance
of specific pathogen-free production herds is also an impor-
tant requirement. Many of these steps are currently in place for
many human plasma-derived FIX products, animal cell-derived
products such as BeneFix®, and animal products such as hepa-
rin and porcine FVIII (Hyate:C®). The process technology for
implementing these steps with transgenic animal-derived
products has been demonstrated to be directly transferable
[28].
Clinical experience with the porcine-derived FVIII product
Hyate:C® is instructive for assessing and reducing the risks
involved in zoonosis from porcine derived therapeutic protein
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products. Hyate:C® is a product alternative used to treat hae-
mophilia A patients who develop an immune response to
plasma-derived or recombinant human FVIII. These patients
produce antibodies (inhibitors) that neutralize the activity of
these FVIII products. Hyate:C® was originally produced using
largely unregulated slaughterhouse pigs, and had been given
to patients since 1984 without any viral-inactivation steps in
the purification process. In 1996, detection of porcine parvo-
virus (PPV) DNA in multiple batches halted production. In a
comprehensive retrospective study of haemophiliacs receiving
Hyate:C® prior to 1996, it was concluded there was no evi-
dence of transmission of PV, encephalomyocarditis virus, or
porcine respiratory and reproductive syndrome virus to pa-
tients receiving Hyate:C®[29]. Thus, the threat of the most
common pathogens that occur in pigs has been evaluated for a
haemophilia therapy derived specifically from pigs having ex-
posure to these diseases. Another example of a safety concern
for parenteral therapeutics is transmissible spongiform en-
cephalopathies such as bovine spongiform encephalopathy
(BSE). It has been recently shown that swine are resistant to
nutritional challenges of highly infective tissue homogenates
from BSE-infected cattle [30]. In addition, specific pathogen-
free transgenic production herds can be fed only plant-derived
diets.
Alternative delivery routes for FVIII and FIX enabled
by abundant supply
Alternative delivery methods that increase the quality of life for
haemophilia patients might be made possible if an abundance
of haemophilic factors were available. While these alternatives
to intravenous infusion increase the ease of administration,
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they decrease the bioavailability, and therefore their applica-
tion is limited by the lack of abundance of haemophilic factors.
For example, aerosolization of FIX may provide an alternative,
needle-free therapeutic option for delivery of FIX across the
epithelial cell layer in the lungs [31]. This recent study demon-
strated that bioavailabilities of 11% (relative to intravenous ad-
ministration) were obtained in haemophilia B dogs using 200 IU
kg-1-bodyweight intratracheal dosing regimen. The pharma-
cokinetic results were consistent with a slow release from a
deposition site in the lungs. This intratracheal administration
produced therapeutic levels of both antigen and activity, and
the activity was detected through 72 h post-administration. In
addition, there has been a group of studies to determine the
absorption rate and bioavailability of plasma-derived FIX ad-
ministered through other extravascular routes: subcutaneous,
intramuscular, and intraperitoneal [32,33]. While all of these
routes resulted in measurable FIX activity, the subcutaneous
and intramuscular injections resulted in bioavailabilities of
63.5% and 82.8%, respectively, in the haemophilia B dog model
[32]. Subcutaneous administration of high concentrations of up
to 4,000 IU mL-1 resulted in bioavailabilities of 35% in cyno-
molgus monkeys and 46% in haemophilia B dogs [33]. Impor-
tantly, while all of these extravascular delivery routes are less
efficient than intravenous, they provide a combination of sim-
plicity of administration and sustained FIX activity. These ad-
vantages may be greatest when applied to factor prophylaxis in
children, for whom intravenous access is most troublesome,
the level of physical activity (and coincident risk of bleeding)
greatest, and yet the total dose requirements are smaller, as
they are based on bodyweight. Thus, if an abundant and eco-
nomical source of FIX were available, then the advantage of
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clinical simplicity becomes a more important and feasible con-
sideration.
Oral dosage formulations
An oral dosage form of FVIII or FIX may provide the most facile
and convenient delivery, especially in children, in whom intra-
venous delivery is problematic. Oral dosage is feasible only
when abundance and cost are favourable, and low patient
plasma levels are needed to achieve effective therapy. In gen-
eral, low bioavailability of oral protein dosage forms arise from
degradation within the gastrointestinal environment and the
resistance of high molecular weight proteins to transport
through the mucus gel layer and epithelia and into the blood-
stream. The inefficiency due to the gastrointestinal environ-
ment can be mitigated by the following: modifying the pH of
the stomach; competitively inhibiting pancreatic proteases with
inhibitors such as soybean trypsin inhibitor, aprotinin, or ca-
sein; and high dosage regimens. A low efficiency of FVIII or FIX
absorption will be less cost-intensive in children and infants
compared with adults because total body weight is low, and
therefore total units needed to reach therapeutic levels is
lower. For example, in the case of FIX and FVIII, only about 5%
of normal plasma levels are needed to prevent spontaneous
bleeding and chronic recurrent arthropathy. This translates to
only about 250 and 12 ng mL-1 of plasma for FIX and FVIII,
respectively. These levels have been achieved in human and
dog plasma using liposome and enzyme-inhibitor formulations
of oral dosages of human plasma-derived FVIII and FIX [34,35].
Hemker et al. [34] formulated plasma-derived FVIII in li-
posomes, administered a dose of 290 U to a haemophilia A
adult patient, and obtained greater than 5% FVIII activity in
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plasma for 50 h after dosing. The profile is consistent with a
slow absorption process resulting in a broad plasma-level re-
sponse. A broad plateau of 5% activity or greater sustained
over more than 48 h is desirable. Horikoshi et al. [35] also used
a liposomal formulation, administered a dose of 14 U of
plasma-derived FIX kg-1 bodyweight in a 9.2-kg dog, and
measured 125% of normal FIX activity by activated partial
throboplastin time. In both these FVIII and FIX oral-dosage
studies, however, sufficient numbers of animal or human sub-
jects were not investigated to assess the variability in
bioavailability that would be expected using oral dosage. It is
likely that at that time, the supply of plasma-derived materials
precluded the effective parametric study of appropriate for-
mulations to determine optimum bioavailability.
Conclusions
The relationship of the structure and function of FVIII and FIX
requires they be made in a mammalian cell. The pig mammary
epithelial cell can make the post-translational modifications
needed for a functional, recombinant human FIX with desirable
pharmacokinetic properties. The high cell density of the mam-
mary gland enables prodigious concentrations of FIX to be
made in the milk. The low milk volumes required would enable
a rapid scale-up to manufacturing an abundant supply of FIX
that would meet clinical demand for prophylactic treatment
that is not currently being met by conventional animal cell bio-
reactor technology. Recognition of the potential for transgenic
animal production of haemophilic factors was recently con-
firmed by the Medical and Scientific Advisory Committee (MA-
SAC) of the United States National Haemophilia Foundation.
They state in their Recommendations [36] that manufacturers
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should strive to make coagulation products less expensive and
that methods such as the use of transgenic animals would in-
crease supply and availability. It is also clear that alternative
delivery methods that dramatically improve the ease of treat-
ment and quality of patient life, particularly for children, will be
feasible if an abundance of haemophilic factors becomes
available. This may apply even more strongly to locations
where patient care and compliance are more challenging due to
economic conditions.
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